Edwards Lifesciences reports Q1 2026 results Wednesday after market close. The medical device maker posts earnings as short interest has declined 19% over the past week to 1.72% of float.
Short sellers have backed away from the $79.71 stock. Over the past month, short interest jumped 23% but remains modest at 9.97 million shares. Cost to borrow sits at just 0.51% and utilization stands at 0.89%, suggesting minimal borrowing pressure.
The options market signals heightened caution. Put-call ratio reached 1.59, more than two standard deviations above its 20-day mean of 1.39. This bearish tilt precedes the earnings announcement scheduled for 8 p.m. ET Wednesday.
The stock has struggled recently. Shares fell 2.1% Monday and are down 3.4% over the past month, though they remain up 1.9% from last week. Year-to-date performance shows a 6.5% decline.
Edwards operates in the health care equipment sector with transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) driving growth. The company generated $6.67 billion in revenue with $1.68 billion in net income. ORTEX Stock Score stands at 75, reflecting strong quality and growth metrics.
Analysts see 21% upside potential from current levels. Days to cover remains low at 1.23, indicating short sellers could exit positions quickly if needed.
This is not financial advice. ORTEX data may contain errors.
See the live data behind this article on ORTEX.
Open EW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
